A new study published in the Journal of Clinical Psychopharmacology has found that Risperdal (generic name risperidone) increases the risk of gynecomastia, or male breast tissue growth, in middle-aged men by as much as 69%. Taking the antipsychotic drug is also 40% more likely to lead to the disorder than alternative antipsychotic drugs.
The Risperdal gynecomastia link has strengthened as scientists research the increasing number of Risperdal side effects. Younger patients, particularly boys and male adolescents, may be at an increased risk of developing unwanted breast tissue due to Risperdal use. Foster children are given the drug at disproportionately high rates to address symptoms of attention deficit hyperactive disorder (ADHD).
Risperdal manufacturer Janssen Pharmaceuticals and parent company Johnson & Johnson have already paid millions to settle claims that the company inappropriately marketed Risperdal for unapproved uses. The companies are facing multiple Risperdal lawsuits alleging that the drug caused gynecomastia in young boys who were given the drug.